drugset / Trial / NCT04845139
A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether Nivolumab given intrathecally is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Timeline
- Start
- 2022-07-02
- Primary completion
- 2022-10-30
- Completion
- 2022-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | Other |